Volume 2, # 4 - August, 1996
Table of Contents
|
| STATE-OF-THE-ART MANAGEMENT OF CANCER |
| BREAST CANCER-PART I |
| Epidemiology | 334 |
| Pathogenesis of Breast Cancer | 334 |
| Breast Cancer Etiology and Risk Factors | 335 |
| Age
| 336 |
| Hormonal Risk Factors | 336 |
| Inherited Breast Cancer | 337 |
| ATM | 337 |
| BRCA1 | 337 |
| BRCA2 | 339 |
| Dietary, Environmental and Other Factors | 339 |
| Molecular Markers | 340 |
| MEETING COVERAGE |
| RECENT DEVELOPMENTS IN NUCLEAR MEDICINE |
From the 43rd Annual Meeting of the Society of Nuclear Medicine
Denver, CO, June 3-6, 1996 |
| Coincidence Imaging and Expanded Use of FDG | 340 |
| ADAC Laboratories MCD Camera | 340 |
| Hot Spot Imaging | 341 |
| Staging of Cancer | 342 |
| Breast Scintigraphy to Differentiate Benign from Malignant Lesions | 342 |
| Cancer Imaging with Monoclonal Antibodies and Peptides | 342 |
| Monoclonal Antibody-based Agents | 342 |
| Antisoma | 342 |
| Biomira | 342 |
| Cytogen | 342 |
| Immunomedics | 343 |
| Neoprobe | 344 |
| NeoRx | 344 |
| Radiolabeled Peptides | 345 |
| Mallinckrodt | 345 |
| Diatide | 345 |
| TECHNOLOGY UPDATE |
| CANCER VACCINES: HUMORAL VERSUS CELLULAR IMMUNITY |
| Rationale for Cancer Vaccine Development | 345 |
| Human Immune Response | 346 |
| Vaccines Eliciting a Cellular (T cell) Immune Response | 347 |
| Active Specific Immunotherapy (ASI) | 348 |
| Biomira | 348 |
| ImmunoTherapy Corporation | 348 |
| Progenics Pharmaceuticals | 349 |
| ASI Using Anti-Idiotypic Antibodies | 349 |
| ImClone Systems | 350 |
| Passive Immunotherapy | 350 |
| Centocor | 351 |
| Vaccines Eliciting a Cellular (T cell) Immune Response | 351 |
| Tumor Antigen Vaccines | 352 |
| Cytel | 352 |
| Lidak Pharmaceuticals | 353 |
| Heat Shock Proteins | 353 |
| Antigenics | 353 |
| StressGen Biotechnologies | 353 |
| Adoptive (Cellular) Immunotherapy | 353 |
| Cancer Vaccines that Stimulate Both vHumoral and Cell-Mediated Immunity | 353 |
| Allogeneic Tumor Cell Vaccines | 354 |
| Ribi ImmunoChem Research | 354 |
| Gene Transfer Into Tumor Cells | 354 |
| Somatix Therapy | 355 |
| Therion Biologics | 355 |
| Vical | 355 |
| Potential Markets for Cancer Vaccines | 355 |
